The Food and Drug Administration (FDA) has issued a formal warning that the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and also used in generic versions of the drug) has been linked to compulsive urges, which can lead to uncontrollable gambling, among other addictions. These rare but serious impulse-control problems reportedly stop when the medicine is discontinued or markedly reduced in dosage. [Read more…]
In 2012, more than 14,000 patients across the U.S. were injected with a contaminated medication that caused an outbreak of potentially deadly fungal meningitis. The New England Compounding Center (“NECC”) in Framingham, Massachusetts, manufactured and sold the drug – an epidural steroid treatment designed to relieve back pain. The contaminated steroid was sold to patients at a number of pain clinics. Nearly 800 patients developed fungal meningitis, and more than 70 patients died. [Read more…]
As revealed in a recent civil lawsuit, certain household and body products containing talcum powder have been linked to ovarian cancer in women. A Missouri jury reached a verdict of $72 million against Johnson & Johnson in a case claiming the health care company’s baby powder product containing talcum caused the decedent plaintiff’s ovarian cancer. This marks the first suit among the more than 1,000 talc exposure cases filed nationwide to result in a jury verdict for the plaintiff. [Read more…]
As reported in The Tennessean, the U.S. Department of Health and Human Services has been requested to waive Medicare liens on payments from the victims compensation fund slated for those sickened or killed in the 2012 nationwide meningitis outbreak resulting from contaminated medication. [Read more…]
According to the Center for Disease Control and Prevention’s National Health Interview Survey in 2014, 2.2% of children ages 3 to 17 (about 1 in 45) have been diagnosed with autism in the United States. [Read more…]
Sarah R. London and Paulina do Amaral of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announce that Paul Ramirez and Dulce A. Morga, residents of Los Angeles County, California, have filed a personal injury lawsuit against pharmaceutical giant GlaxoSmithKline LLC (“GSK”) for injuries leading to the death of their infant daughter, Baby Sarah Ramirez Morga, allegedly as a result of Ms. Morga being prescribed GSK’s drug ondansetron (brand name Zofran) while pregnant.
Sarah R. London and Paulina do Amaral of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announce that Robin and Stanley Zgurski, residents of Florida, have filed a personal injury lawsuit against pharmaceutical giant GlaxoSmithKline LLC (“GSK”) for the injuries suffered by their son allegedly as a result of Ms. Zgurski being prescribed GSK’s drug ondansetron (brand name Zofran) while pregnant. [Read more…]
As reported by Law360, the US Judicial Panel on Multidistrict Litigation has consolidated in Massachusetts a number of lawsuits alleging that off-label promotion by GlaxoSmithKline of its anti-nausea drug Zofran for morning sickness led to serious birth defects. “The MDL panel found that 12 lawsuits, some of which are proposed class actions, warranted consolidation as they all involved common allegations that GlaxoSmithKline’s Zofran and its generic equivalent, Ondansetron … cause birth birth defects in children when their mothers ingest the drug while pregnant.” [Read more…]
Sarah R. London of the national plaintiffs’ law firm Lieff Cabraser Heimann & Bernstein, LLP, announced that Katherine and Matthew Murray, residents of Alameda County, California, have filed a personal injury lawsuit against pharmaceutical giant GlaxoSmithKline LLC (“GSK”) for the injuries suffered by their daughter allegedly as a result of Ms. Murray being prescribed while pregnant GSK’s drug ondansetron, sold under the brand name Zofran.
The story behind a drug called Risperdal has a long and winding tail. And it is a story that has had devastating results for many American families.
Benicar is a widely prescribed medication for blood pressure and hypertension (chronic high blood pressure). Olmesartan is the active ingredient of Benicar and is also contained in Benicar HCT, Tribenzor, and Azor.
Lieff Cabraser attorney Lexi J. Hazam is speaking at HarrisMartin’s MDL Conference: Zofran, Bard IVC and Zimmer Persona Knee Litigation on July 29, 2015 at Hotel Nikko in San Francisco. Hazam will be featured as a panelist discussing the Benicar (Olmesartan) Litigation. Hazam has been appointed by the court overseeing the nationwide Benicar MDL litigation to the Plaintiffs’ Steering Committee, and serves as Co-Chair of the MDL Plaintiffs’ Science and Experts Committee.
In a significant development in the Actos litigation, the California State Appeals Court for the Second District last week reinstated a cancer patient and spouse’s $6.5 million jury award against the makers of Actos, a diabetes medication. The appellate court’s decision reaffirms the importance and role of the jury in deciding claims.
Lieff Cabraser attorney Lexi J. Hazam was elected Vice Chair of the American Association for Justice’s (AAJ) Section on Toxic, Environmental and Pharmaceutical Torts (STEP). Promoting a fair and effective justice system, AAJ’s mission is to support the representation of those injured by the harmful misconduct and negligence of others. STEP is a section of the association, which focuses on pharmaceutical toxic effects, medical devices, pesticides, consumer products, industrial pollution, and other environmental damages.
Parents charge that Zofran (generic name ondansetron) is a dangerous and defective drug because its use by pregnant women can lead to serious birth defects. Zofran was approved by the FDA in 1991 to treat extreme nausea from chemotherapy and later expanded for use as a treatment for serious surgical nausea. Lawsuits allege that the drug has been marketed off-label by GlaxoSmithKline to obstetricians and gynecologists to prescribe to their pregnant patients to control the pregnancy nausea commonly referred to as “morning sickness.”
Lieff Cabraser attorney Lexi J. Hazam announced that three patients prescribed olmesartan, a widely-prescribed blood pressure medication sold under the brand name Benicar, along with Benicar HT, Tribenzor and Azor, recently filed lawsuits against Japan-based Daiichi Sankyo, Benicar’s manufacturer, and Forest Laboratories, which marketed and distributed Benicar in the United States.
The U.S. Food and Drug Administration has warned that patients with high blood pressure taking Benicar could suffer serious side effects including chronic diarrhea, unusual weight loss, and severe gastrointestinal problems.
The California Supreme Court today resoundingly endorsed consumers’ right to challenge pharmaceutical pay-for-delay settlements under California competition law.
On April 28, 2015, U.S. District Court Judge Rebecca F. Doherty, the judge overseeing the Actos injury cases in federal court nationwide, issued an order recognizing that Takeda, the manufacturer of Actos, has agreed to settle all bladder cancer claims brought against the company by Actos users who satisfy the following three conditions:
Zofran has become a widely popular morning sickness treatment. Physician expectations were that the anti-nausea drug would benefit the patient, but GlaxoSmithKline, the manufacturer of Zofran, allegedly provided little information on the drug’s effect on unborn children. In numerous lawsuits, parents charge that GlaxoSmithKline failed to warn about an association between Zofran and certain very specific birth defects such as cleft palate and heart defects.